Results 21 to 30 of about 2,249 (191)

Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison [PDF]

Dermatology and Therapy
Introduction Dupilumab and lebrikizumab have demonstrated efficacy in atopic dermatitis (AD) clinical trials; however, no direct comparisons exist. Methods Efficacy outcome achievement (dupilumab and lebrikizumab with topical corticosteroids [TCS]) at 16 
Sonja Ständer, Andreas Pinter, Firas G. Hougeir, Patricia Guyot, Yingxin Xu, Amy H. Praestgaard, Nick Freemantle, Ana B. Rossi, Gaëlle Bégo-Le-Bagousse, Zhixiao Wang, Kerry Noonan, Mike Bastian   +11 more
doaj   +2 more sources

Therapeutic Potential of Lebrikizumab in the Treatment of Atopic Dermatitis

Journal of Asthma and Allergy, 2020
Tiffany Y Loh,1 Jennifer L Hsiao,2 Vivian Y Shi1 1University of Arizona, Division of Dermatology, Tucson, AZ, USA; 2University of California Los Angeles, Division of Dermatology, Los Angeles, CA, USACorrespondence: Vivian Y ShiDivision of Dermatology ...
Loh TY, Hsiao JL, Shi VY
doaj   +5 more sources

Profile of lebrikizumab and its potential in the treatment of asthma

Journal of Asthma and Allergy, 2015
Diego Jose Maselli,1 Holly Keyt,1 Linda Rogers,2 1Department of Medicine, Division of Pulmonary Diseases and Critical Care, University of Texas Health Science Center at San Antonio, San Antonio, TX, 2Pulmonary, Critical Care, and Sleep Medicine ...
Maselli DJ, Keyt H, Rogers L
doaj   +5 more sources

Incidence of upper respiratory tract infections with biological therapies in moderate to severe atopic dermatitis: a systematic review and meta-analysis [PDF]

Frontiers in Medicine
IntroductionAtopic dermatitis (AD) is a chronic inflammatory skin condition affecting 5%−20% of children and 2%−10% of adults worldwide. Treatment for moderate-to-severe AD includes biologics like dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors
Rose Alraddadi, Rose Alraddadi, Mulham Kalantan, Mulham Kalantan, Yara Aljefri, Yara Aljefri, Hadeel Maaddawi, Abdulrahman Alsamadani, Abdulrahman Alsamadani, Athoub Kadasa, Athoub Kadasa, Abdulrahman Softah, Abdulrahman Softah, Baraa Tabbakh, Baraa Tabbakh, Rahaf Alturkistani, Abdulhadi Jfri, Abdulhadi Jfri, Abdulhadi Jfri   +18 more
doaj   +2 more sources

Efficacy of Lebrikizumab on Pruritus: A Narrative Review. [PDF]

Adv Ther
Atopic dermatitis (AD) is a chronic, relapsing, and heterogeneous skin disease characterized by eczematous morphology and intense pruritus, significantly impacting the quality of life of affected individuals. A primary cytokine implicated in AD is interleukin-13 (IL-13), which directly drives pruritus skin sensitization, contributing to pruritus ...
Yosipovitch G, Kim BS, Ständer S, Elmariah SB, Prajapati VH, Kabashima K, Gallo G, Rueda MJ, Pierce E, Ding Y, Kwatra SG.   +10 more
europepmc   +4 more sources

Lebrikizumab for adolescent atopic dermatitis: 24-week real-world outcomes from the Czech BIOREP registry [PDF]

JAAD International
Filip Rob, MD, PhD, Blanka Pinková, MD, PhD, Petra Gkalpakioti, MD, Jiřina Bartoňová, MD, Jiří Horažďovský, MD, PhD, Jan Říčař, MD, PhD, Jana Třešňák Hercogová, MD, PhD, Kristýna Sokolová, MD   +7 more
doaj   +2 more sources

Real-world effectiveness and safety of lebrikizumab maintenance dosing every 4 weeks starting at week 4 after 2 loading doses in Japanese patients with atopic dermatitis [PDF]

JAAD International
Yoshiki Okada, MD, Masahiro Kamata, MD, PhD, Shoya Suzuki, MD, Ayu Watanabe, MD, PhD, Chika Chijiwa, MD, PhD, Yayoi Tomura, MD, PhD, Ryosuke Takeshima, MD, PhD, Azusa Hiura, MD, PhD, Kotaro Hayashi, MD, PhD, Atsuko Fukuyasu, MD, PhD, Takamitsu Tanaka, MD, PhD, Takeko Ishikawa, MD, PhD, Yayoi Tada, MD, PhD   +12 more
doaj   +2 more sources

Lebrikizumab for atopic dermatitis. [PDF]

Aust Prescr
europepmc   +6 more sources

Selective IL-13 inhibitors for the treatment of atopic dermatitis

Drugs in Context, 2021
Background: Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases worldwide. AD pathogenesis is multifactorial, involving environmental and genetic factors.
Francisca Gonçalves, Egídio Freitas, Tiago Torres   +2 more
doaj   +1 more source

Virus-Like Particle-Mediated Vaccination against Interleukin-13 May Harbour General Anti-Allergic Potential beyond Atopic Dermatitis [PDF]

, 2020
Virus-like particle (VLP)-based anti-infective prophylactic vaccination has been established in clinical use. Although validated in proof-of-concept clinical trials in humans, no VLP-based therapeutic vaccination against self-proteins to modulate chronic
Foerster, John, Molęda, Aleksandra
core   +2 more sources